Breast Cancer Risk and HRT

Educational only. Not medical advice. Breast cancer risk assessment is individualized. This guide provides context from published evidence but does not replace a clinical evaluation of your personal risk. If you have a personal history of breast cancer, discuss HRT specifically with your oncologist.

Breast cancer risk is the primary concern that keeps women from starting HRT, and the primary reason many clinicians hesitate to prescribe it. The fear is understandable - the 2002 WHI headlines were dramatic and unequivocal. But the evidence beneath those headlines is significantly more nuanced than “HRT causes breast cancer.”

Understanding the actual data - including which types of HRT carry which levels of risk, how that risk compares to other modifiable factors, and what has changed in clinical understanding since 2002 - helps replace fear with informed decision-making.

• Estrogen-only HRT (for women without a uterus) was NOT associated with increased breast cancer risk in the WHI and showed a possible risk REDUCTION
• Combined estrogen-progestogen HRT (specifically CEE + MPA in the WHI) was associated with approximately 8 additional breast cancer cases per 10,000 women per year after 5+ years of use
• The risk from combined HRT is comparable to or less than the risk from 1 to 2 alcoholic drinks daily, obesity, or physical inactivity
• The type of progestogen may matter: emerging evidence suggests micronized progesterone carries lower risk than synthetic MPA, though confirmatory randomized trial data is limited
• Risk increases with duration of combined therapy and decreases after discontinuation
• Individual baseline risk (family history, breast density, prior biopsies) must be part of the conversation

The WHI estrogen-plus-progestin arm (CEE + MPA, in women with a uterus). After an average of 5.6 years, there were 38 cases of invasive breast cancer per 10,000 women per year in the HRT group versus 30 per 10,000 in the placebo group. That is 8 additional cases per 10,000 women per year, or an absolute risk increase of 0.08%.

The WHI estrogen-only arm (CEE without progestogen, in women after hysterectomy). After an average of 7.2 years, there was NO statistically significant increase in breast cancer. In fact, the estrogen-only group showed a trend toward REDUCED breast cancer incidence. After extended follow-up (median 11.8 years), the reduction reached statistical significance.

This is one of the most important distinctions in HRT prescribing and one of the most commonly overlooked in media coverage. Estrogen alone did not increase breast cancer risk in the WHI. The risk signal was specifically with the combination, and specifically with MPA as the progestogen.

The WHI used medroxyprogesterone acetate (MPA), a synthetic progestin. Subsequent research has asked whether different progestogens carry different risks.

The French E3N cohort study (approximately 80,000 women) found that estrogen combined with micronized progesterone was not associated with increased breast cancer risk after 5 years, while estrogen combined with synthetic progestins was associated with increased risk. This is observational data, not a randomized trial, but the signal is consistent and biologically plausible (micronized progesterone has different receptor binding properties than MPA).

The 2019 Lancet meta-analysis found that all types of combined HRT were associated with some increase in breast cancer risk, though with different magnitudes. This analysis grouped heterogeneous data, and some researchers argue it underweights the progesterone-type distinction.

The clinical takeaway: the evidence suggests, but does not definitively prove, that micronized progesterone may carry lower breast cancer risk than synthetic progestins. Many menopause specialists preferentially prescribe micronized progesterone based on this evidence, even while acknowledging the limitations.

Context matters for risk perception.

Drinking 1-2 alcoholic beverages daily increases breast cancer risk by approximately 10 to 20%. Being obese (BMI 30+) increases postmenopausal breast cancer risk by approximately 20 to 40%. Physical inactivity increases risk by approximately 10 to 20%. Combined HRT for 5+ years (WHI data, CEE + MPA): approximately 26% relative increase, translating to 8 additional cases per 10,000 women-years.

These comparisons are not meant to minimize HRT risk. They are meant to calibrate it. Many women who refuse HRT over breast cancer concerns continue to drink wine, remain sedentary, and carry excess weight - all of which carry comparable or greater risk increases. Consistency in risk evaluation is more useful than selective fear.

Regular mammography should continue regardless of HRT status. Standard screening guidelines (mammography every 1 to 2 years starting at age 40 to 50, depending on risk level and guideline followed) apply.

HRT can increase breast density, which can make mammograms harder to interpret. Inform your radiologist that you are on HRT so they can account for this. Women with dense breast tissue may benefit from supplemental screening (breast ultrasound or MRI) regardless of HRT status.

Monthly breast self-awareness (knowing what is normal for you and reporting changes) is recommended by NAMS. Clinical breast exam frequency should be discussed with your clinician.

The WHI combined therapy arm (CEE + MPA): hazard ratio 1.26 (95% CI 1.00-1.59) for invasive breast cancer after mean 5.6 years. In absolute terms: 38 cases per 10,000 women-years versus 30 per 10,000 in placebo. That is 8 additional cases per 10,000 women per year, or 0.08% absolute risk increase per year.

The WHI estrogen-only arm (CEE without progestogen): hazard ratio 0.77 (95% CI 0.59-1.01) for invasive breast cancer after mean 7.2 years. This trended toward REDUCED risk. In extended follow-up (median 11.8 years post-intervention), the reduction reached statistical significance (hazard ratio 0.78, 95% CI 0.63-0.96).

The Lancet 2019 Collaborative Group meta-analysis: pooled data from 58 studies found that all types of combined HRT were associated with excess breast cancer risk, but with notable differences by progestogen type and duration. The risk was lower with intermittent progestogen use versus continuous.

For context, these numbers mean that if 10,000 women take combined HRT for one year, approximately 8 more will develop breast cancer than if those 10,000 women did not take HRT. By comparison, 10 additional cases per 10,000 women per year are attributable to drinking one alcoholic beverage daily. Approximately 20-40 additional cases per 10,000 women per year are attributable to obesity.

Duration-Dependent Risk

The breast cancer risk from combined HRT is not a binary on/off. It increases gradually with duration and decreases after discontinuation.

Years 1 to 3 of combined therapy: minimal to no measurable increase in breast cancer risk above baseline. Years 3 to 5: risk begins to emerge in some studies, though the absolute increase remains small. Years 5+: the WHI signal became statistically significant at mean 5.6 years of use. The hazard ratio of 1.26 applies to this timeframe. After discontinuation: risk declines. Within 3 to 5 years of stopping combined therapy, risk returns to approximately baseline levels (though some studies suggest a slight residual elevation).

For estrogen-only therapy: no increased risk was observed even after 7+ years in the WHI. Extended follow-up showed a persistent trend toward reduced risk.

What this means practically: short-term combined HRT (under 5 years) for severe symptoms carries very low breast cancer risk. Longer-term use requires ongoing reassessment, particularly for women with additional risk factors. Estrogen-only therapy (for women without a uterus) has a more favorable long-term profile and may be appropriate for extended duration with less concern about breast cancer.

The Risk Factors You Can Modify

While discussing HRT breast cancer risk, it is worth noting the risk factors that are entirely within your control and carry comparable or greater risk. Reducing alcohol to fewer than 3 drinks per week, maintaining a healthy BMI (obesity increases postmenopausal breast cancer risk by 20 to 40%), regular physical activity (150+ minutes per week reduces risk by approximately 10 to 20%), and consistent mammographic screening all have measurable impact on breast cancer outcomes. A woman who declines HRT over breast cancer fear but drinks a glass of wine nightly, is sedentary, and skips mammograms has not reduced her risk - she has shifted it from one category to another while losing the symptom relief, bone protection, and potential cardiovascular benefit that HRT provides.

• What is my individual breast cancer risk based on family history, breast density, and other factors?
• Should I have a formal risk assessment (Gail model or Tyrer-Cuzick) before starting HRT?
• How does the type of HRT you are recommending relate to breast cancer risk in the evidence?
• If I am concerned about breast cancer risk, would estrogen-only therapy (if I have had a hysterectomy) or micronized progesterone (if I have a uterus) reduce my risk compared to other options?
• How does HRT use affect my mammography schedule or interpretation?
• At what point should I reassess the risk-benefit balance of continuing HRT?